Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung.
Glypican-1
immunohistochemistry
lung adenocarcinoma
lung squamous cell carcinoma
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
ppublish
Résumé
The histological classification of non-small cell lung cancer (NSCLC) is essential in determining new cancer-specific targeted therapies. However, the accurate typing of poorly differentiated is difficult, particularly for poorly differentiated squamous cell carcinoma and adenocarcinoma of the lung with limited immunohistochemical markers. Thus, novel immunohistochemical markers are required. We assumed the possibility of the immunohistochemical expression of glypican-1 in lung squamous cell carcinoma. The microarray dataset GSE43580 from Gene Expression Omnibus database were analyzed for confirming the gene expression of glypican-1 in lung squamous cell carcinoma. We immunohistochemically investigated the use of glypican-1 as a novel positive diagnostic marker for lung squamous cell carcinoma. Glypican-1 expression in 63 cases of poorly differentiated lung squamous cell carcinoma and 60 cases of solid predominant lung adenocarcinoma was investigated by immunohistochemistry. Additionally, we compared glypican-1 expression with the expressions of p40, cytokeratin 5/6, thyroid transcription factor-1 (TTF-1), and napsin A. All 63 cases of lung squamous cell carcinoma showed glypican-1 expression. In contrast, only 2 cases of lung adenocarcinoma showed glypican-1 expression. The sensitivity, specificity, and diagnostic accuracy of glypican-1 expression for differentiating lung squamous cell carcinoma from lung adenocarcinoma were 100%, 96.7%, and 98.4%, respectively. These were similar to those of p40 and significantly better than those of CK 5/6. We recommend the use of glypican-1 as an additional positive marker of lung squamous cell carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
The histological classification of non-small cell lung cancer (NSCLC) is essential in determining new cancer-specific targeted therapies. However, the accurate typing of poorly differentiated is difficult, particularly for poorly differentiated squamous cell carcinoma and adenocarcinoma of the lung with limited immunohistochemical markers. Thus, novel immunohistochemical markers are required. We assumed the possibility of the immunohistochemical expression of glypican-1 in lung squamous cell carcinoma.
METHODS
METHODS
The microarray dataset GSE43580 from Gene Expression Omnibus database were analyzed for confirming the gene expression of glypican-1 in lung squamous cell carcinoma. We immunohistochemically investigated the use of glypican-1 as a novel positive diagnostic marker for lung squamous cell carcinoma. Glypican-1 expression in 63 cases of poorly differentiated lung squamous cell carcinoma and 60 cases of solid predominant lung adenocarcinoma was investigated by immunohistochemistry. Additionally, we compared glypican-1 expression with the expressions of p40, cytokeratin 5/6, thyroid transcription factor-1 (TTF-1), and napsin A.
RESULTS
RESULTS
All 63 cases of lung squamous cell carcinoma showed glypican-1 expression. In contrast, only 2 cases of lung adenocarcinoma showed glypican-1 expression. The sensitivity, specificity, and diagnostic accuracy of glypican-1 expression for differentiating lung squamous cell carcinoma from lung adenocarcinoma were 100%, 96.7%, and 98.4%, respectively. These were similar to those of p40 and significantly better than those of CK 5/6.
CONCLUSIONS
CONCLUSIONS
We recommend the use of glypican-1 as an additional positive marker of lung squamous cell carcinoma.
Identifiants
pubmed: 33718020
doi: 10.21037/tlcr-20-857
pii: tlcr-10-02-766
pmc: PMC7947391
doi:
Types de publication
Journal Article
Langues
eng
Pagination
766-775Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-857). The authors have no conflicts of interest to declare.
Références
Appl Immunohistochem Mol Morphol. 2014 May-Jun;22(5):377-82
pubmed: 24805133
Am J Surg Pathol. 2015 Sep;39(9):1170-80
pubmed: 25871623
Bioessays. 2007 Aug;29(8):758-71
pubmed: 17621645
J Clin Oncol. 2004 Jun 1;22(11):2184-91
pubmed: 15169807
Mod Pathol. 2012 Mar;25(3):405-15
pubmed: 22056955
Histopathology. 2003 Nov;43(5):444-52
pubmed: 14636270
BMC Cancer. 2016 Sep 29;16(1):760
pubmed: 27681076
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mod Pathol. 2018 May;31(5):809-815
pubmed: 29327712
Am J Surg Pathol. 2012 Jun;36(6):895-9
pubmed: 22367298
World Neurosurg. 2017 Sep;105:282-288
pubmed: 28602885
Curr Oncol Rep. 2019 Feb 26;21(3):21
pubmed: 30806814
Mod Pathol. 2011 Oct;24(10):1348-59
pubmed: 21623384
Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):648-659
pubmed: 26447895
J Am Soc Cytopathol. 2016 May-Jun;5(3):123-132
pubmed: 27699149
Sci Rep. 2018 Jan 9;8(1):134
pubmed: 29317712
Clin Cancer Res. 2012 May 1;18(9):2443-51
pubmed: 22407829
J Clin Invest. 1998 Nov 1;102(9):1662-73
pubmed: 9802880
J Thorac Oncol. 2016 Jun;11(6):862-72
pubmed: 26872818
J Pathol Transl Med. 2018 Sep;52(5):283-289
pubmed: 30235512
Bioinformatics. 2013 Nov 15;29(22):2892-9
pubmed: 23966112
Cancer Res. 2001 Jul 15;61(14):5562-9
pubmed: 11454708
Br J Cancer. 2016 Jun 28;115(1):66-75
pubmed: 27310703
Pathology. 2019 Apr;51(3):240-245
pubmed: 30798982
Mod Pathol. 2006 Mar;19(3):417-28
pubmed: 16415794
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Int J Surg Pathol. 2013 Jun;21(3):229-39
pubmed: 23486764
Histopathology. 2017 Feb;70(3):375-384
pubmed: 27589012
Am J Pathol. 2006 Jun;168(6):2014-26
pubmed: 16723715
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Int J Surg Pathol. 2010 Jun;18(3):161-72
pubmed: 20460313